Table 1 Patient characteristics and treatment profile of whole patients and comparison of two subgroups
From: Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients
Characteristic | Median (range)/no. of patients (%) | p -value | ||
|---|---|---|---|---|
Total | Group A | Group B | ||
Age (year) | NS | |||
Median | 50 | 49 | 51 | |
Range | 22-77 | 22-74 | 29-77 | |
ECOG performance status | NS | |||
0-1 | 47 (94.0) | 34 (97.1) | 13 (86.7) | |
2-3 | 3 (6.0) | 1 (2.9) | 2 (13.3) | |
Histopathologic type | 0.043 | |||
Squamous cell ca | 42 (84.0) | 32 (91.4) | 10 (66.7) | |
Adenocarcinoma | 5 (10.0) | 3 (8.6) | 2 (13.3) | |
Small cell ca | 2 (4.0) | 2 (13.3) | ||
Adenosquamous cell ca | 1 (2.0) | 1 (6.7) | ||
Pre-treatment Hb (g/dL) | NS | |||
≤ 10 | 16 (32.0) | 10 (28.6) | 6 (40.0) | |
>10 | 34 (68.0) | 25 (71.4) | 9 (60.0) | |
Tumor size (cm) | NS | |||
≤4 | 14 (28.0) | 12 (34.3) | 2 (13.3) | |
>4 | 36 (72.0) | 23 (65.7) | 13 (86.7) | |
Dissemination pattern | ||||
Group A | 35 (70.0) | |||
Group B | 15 (30.0) | |||
Treatment type | NS | |||
RT + CTx | 39 (78.0) | 25 (71.4) | 14 (93.3) | |
RT alone | 11 (22.0) | 10 (28.6) | 1 (6.7) | |
RT field | <0.001 | |||
Whole pelvis | 18 (36.0) | 7 (20.0) | 11 (73.3) | |
Extended | 32 (64.0) | 28 (80.0) | 4 (26.7) | |
RT dose (Gy) | NS | |||
External dose | 45.0 (43.2-54.0) | 45.0(43.2-52.0) | 45.0 (44.0-54.0) | |
ICR dose | 30.0 (18.0-39.0) | 30.0 (18.0-39.0) | 30.0 (21.0-30.0) | |
Point A dose (EQD2) | 75.5 (64.5-94.25) | 72.9 (64.5-94.25) | 75.5 (67.9-87.5) | |